Cellebrite DI Stock-Based Compensation Growth & History (CLBT)

Cellebrite DI's stock-based compensation was $44.9M for fiscal 2025.

View full Cellebrite DI company overview

Cellebrite DI annual stock-based compensation history

Cellebrite DI annual stock-based compensation

Fiscal yearPeriod endedStock-based compensationChangeGrowth
20252025-12-31$44.9M$14.3M+46.83%
20242024-12-31$30.6M$11.6M+60.94%
20232023-12-31$19.0M$5.3M+38.59%
20222022-12-31$13.7M$7.2M+111.54%
20212021-12-31$6.5M−$791,000−10.88%
20202020-12-31$7.3M−$5.5M−43.01%
20192019-12-31$12.8M

Cellebrite DI stock-based compensation trends

Over the last five fiscal years, Cellebrite DI's stock-based compensation increased from $7.3M to $44.9M, a change of $37.6M. The latest reported quarter, Q2 2026, shows $15.2M.

About the metric

What stock-based compensation means

Stock-based compensation is the expense associated with equity awards such as restricted stock and employee options. It is a non-cash expense when recognized, but it can dilute existing shareholders unless offset by share repurchases.

Calculation and source

SEC-reported stock-based compensation

TickerStat standardizes share-based compensation reported in company SEC filings. The history shows recognized compensation expense or its cash-flow-statement adjustment, not the grant-date value of new awards or a forecast of future dilution. Fiscal periods can differ from calendar years, so exact period-end dates are included.

Review Cellebrite DI source filings ↗

Community posts

It’s quiet here.

No posts about CLBT yet. Start the conversation.

Write the first post